An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion.

Trial Profile

An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2010

At a glance

  • Drugs SLV 334 (Primary)
  • Indications Chronic brain damage
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 03 Apr 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Apr 2010 Actual initiation date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top